Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer

Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer


Kenvue, a unit of Johnson & Johnson’s consumer health business.

CFOTO | Future Publishing | Getty Images

Johnson & Johnson on Monday said it plans to reduce by at least 80% its stake in Kenvue, the consumer health business it spun out as an independent company earlier this year, via a stock exchange offer.

J&J owns 89.6% of Kenvue’s common stock, which amounts to more than 1.72 billion shares. 

related investing news

We're selling some shares of this health-care company and changing our rating

CNBC Investing Club

The exchange offer, also known as a split-off, will allow J&J shareholders to swap all or a portion of their shares for Kenvue’s common stock at a 7% discount. The offer is expected to be tax-free, J&J said in a release. 

The company noted that the split-off is voluntary for investors and is slated to close on Aug. 18, which is far earlier than expected.

J&J said it received a waiver that dismisses the share lockup period associated with Kenvue’s initial public offering in May. That lockup agreement would have required J&J to wait 180 days to sell any of its shares. 

“We believe now is the right time to distribute our Kenvue shares, and we are confident that a split-off is the appropriate path forward to bring value to our shareholders,” J&J CEO Joaquin Duato said in a statement. 

Duato added that the split-off will sharpen J&J’s focus on its pharmaceutical and medtech businesses – both of which helped the company beat on second-quarter revenue and adjusted earnings last week. 

J&J first announced its intent to launch an exchange offer in its second-quarter earnings report on Thursday, but the company provided few details on the plan. Shares of Kenvue fell following that announcement, despite second-quarter results that also topped Wall Street estimates. 

When asked about J&J’s planned exchange offer on Thursday, Kenvue CEO Thibaut Mongon told CNBC’s “Squawk on the Street” that the company is “pleased with the way that the IPO has been received by shareholders.”

“We see a lot of alignment among our new investors in seeing the potential of Kenvue, but I can tell you that we are fully ready to leave as a fully independent company,” he said. 



Source

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
Health

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly

Daniel Grill | Tetra Images | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1 pills for obesity are closer than ever.  2026 is likely the year that two new oral weight loss […]

Read More
Pfizer’s modest 2026 outlook shows its big investments will take time to pay off
Health

Pfizer’s modest 2026 outlook shows its big investments will take time to pay off

Smith Collection | Archive Photos | Getty Images Pfizer on Tuesday forecast modest 2026 guidance as it looks to longer-term investments in its pipeline to counter waning Covid product sales and declines from older drugs. Those hurdles aren’t surprising or new for Pfizer, which has seen a dramatic decline in Covid vaccine and antiviral sales […]

Read More
Trump says he’s ‘strongly’ considering reclassifying pot via executive order
Health

Trump says he’s ‘strongly’ considering reclassifying pot via executive order

Bill Schmitt Jr. (C) joins cannabis reform protesters outside the White House to call on U.S. President Joe Biden “to take action on cannabis clemency before the November general election” October 24, 2022 in Washington, DC. Win Mcnamee | Getty Images Pot stocks failed to light up for a second day on Monday even after […]

Read More